beta2-Microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma.
The potential negative impact of HLA class I antigen abnormalities on the outcome of T cell-based immunotherapy of melanoma has prompted us to investigate the mechanisms underlying lack of HLA class I antigen expression by melanoma cell lines Me18105, Me9923, and Me1386. Distinct mutations in the be...
שמור ב:
| הוצא לאור ב: | J Clin Invest |
|---|---|
| Principais autores: | , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
American Society for Clinical Investigation
1998
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC508863/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/9637706/ https://ncbi.nlm.nih.govhttps://doi.org/10.1172/JCI498 |
| תגים: |
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|
